Barely Significant
← all excerpts

Sacubitril/valsartan for the prevention of cancer therapy-related cardiac dysfunction: a systematic review and meta-analysis.

Cardiooncology · 2026 · PMC13231533 · PMID 42015207

Europe PMCDOI
1
hedged sentence
0.0740
closest p · 1.5× alpha
0.0740
boldest claim

The sentences

did not reach statistical significancep = 0.074so close (0.05 < p ≤ 0.1)
The pooled analysis showed a significant reduction in DBP with sacubitril/valsartan treatment (MD − 4.06 mmHg; 95% CI − 8.01 to − 0.11; p = 0.047), whereas the reduction in SBP did not reach statistical significance (MD − 7.71 mmHg; 95% CI − 16.76 to 1.37; p = 0.074) (Supplementary figure S5G&H).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.